Founder / systems builder
Varun Sharma
- Founder, VARUNÉ Labs
- Founder, CEO & CTO, NEUVIOR
- Product architect, PHARMORIS
Building the chain between medicines intelligence, scientific development and the future infrastructure required to turn evidence into accountable action.
- Glasgow-born
- British-Indian perspective
- Medicines + intelligent systems
Founder thesis
Build the chain.
Keep every link honest.
Varun's thesis is that medicines intelligence, formulation, development, manufacturing and physical infrastructure should inform one another without being presented as one finished system before the evidence exists.
His published account traces his earliest commercial education to his family's Glasgow corner shop: stock, cash, trust and poor decisions became visible quickly. The setting changed from shelves and tills to pharmaceuticals and technology; the operating test did not.
NEUVIOR is the current pharmaceutical company. PHARMORIS is its immediate product priority. VARUNÉ Labs makes a separate scientific and infrastructure horizon visible. VYRONIS remains a separate research direction. Each must retain its own legal, funding, evidence and operating status.
- 01 / Now
Make the immediate product useful.
Define the buyer problem, controlled workflow, assurance route and evidence required for PHARMORIS to earn evaluation.
- 02 / Next
Test the infrastructure case.
Reduce uncertainty around demand, location, operator, utilities, planning, regulation, capital and phased economics.
- 03 / Horizon
Connect capability only when justified.
Bring laboratories, automation and manufacturing together only after rights, approvals, quality systems and demand support the move.
Founder + company funding record
£217,542.37 secured non-dilutive project backing.
NEUVIOR's public record spans three awarded programmes plus £43,000 in secured private non-dilutive match funding. It is stated here as evidence of founder execution, with the active SMART:SCOTLAND project and the separate VARUNÉ campus-capital boundary kept explicit.
Three awarded programmes plus £43,000 in secured private non-dilutive match funding
- 01Awarded programme£25,000
VIONIX ZERO
Innovate UK
Public UKRI Gateway to Research record.
Open the UKRI organisation record - 02Awarded programme£49,928
PHARMORIS
Innovate UK
Public UKRI Gateway to Research record.
Open the UKRI organisation record - 03Awarded · active projectUp to £99,614.37
PHARMORIS - AI Feasibility for NHS Generics Access
Scottish Enterprise SMART:SCOTLAND · project 2025_00003995
Signed offer accepted on 14 April 2026; signed eligible project budget £144,020.53.
Read public award coverage - 04Secured private match funding£43,000
SMART:SCOTLAND match funding
Private non-dilutive match funding
Private funding and match-funding record held by NEUVIOR.
Make the future visible. Keep the present truthful.
Concept architecture can make an ambition legible. It cannot evidence a site, approval, partner, facility or operating capability.
Connected founder work
A founder portfolio. Four deliberately separate status records.
The connection shown here is founder-level and thematic. It does not collapse a company, a product, a predevelopment concept and a research direction into one legal or operating claim.
NEUVIOR
Varun is the founder, CEO and CTO of NEUVIOR, a pharmaceutical infrastructure company whose immediate public priority is PHARMORIS.
Visit NEUVIORPHARMORIS
A human-governed medicines operations system intended to connect evidence, accountable decisions, coordinated work and reviewable outcomes.
Review PHARMORISVARUNÉ Labs
A separate founder-led concept for future medicines development, scientific infrastructure, intelligent systems and advanced manufacturing.
Explore the campus thesisVYRONIS
A founder-led research direction exploring space-biology and extreme-environment questions, kept distinct from VARUNÉ Labs and its campus proposals.
Review the research directionOperating doctrine
Ambition becomes credible through gates.
The doctrine is designed to preserve ambition while protecting capital, scientific integrity and public trust.
- 01
Evidence before infrastructure
Every proposed facility should answer a defined scientific, commercial or public-value need before capital becomes irreversible.
- 02
Truth before theatre
A concept can make a possibility legible. It cannot prove land, finance, planning, licences, equipment, partners or operating readiness.
- 03
Human authority before automation
Artificial intelligence and robotics may structure evidence and extend capability; accountable people must still own regulated decisions.
- 04
Partnership before unnecessary ownership
Controlled access and specialist collaboration can be more credible than buying infrastructure before demand, quality and economics are known.
- 05
Review before mythology
Each stage should retain the evidence, decision, owner and reason to advance, change direction or stop.
Published thinking + public record
Publication is evidence of a public argument, not endorsement.
The records below are classified by what they actually are: founder commentary, a reader letter or publisher-authored coverage of a proposal.
- 01Founder commentary
ET Pharma
India's pharma quality reset will be won after the inspector leaves
Publisher metadata identifies Varun Sharma as the author.
Open publisher record - 02Reader letter
Financial Times
Letter: The real test is whether invention leads to adoption
Published under the current name Varun Sharma; this is a reader letter, not staff coverage.
Open publisher record - 03Publisher-authored comment
Pharmaceutical Technology
Why the India-UK trade deal now needs a five-gate implementation ledger
A comment article by Ross Law centred on a proposal from Varun Sharma; it does not establish adoption or endorsement of that proposal.
Open publisher record - 04Founder commentary
PharmaTimes
How we roll
Published under the historical name Varun Cruz.
Open publisher record - 05Founder commentary
Manufacturing Chemist
NICE approval is not enough: why the UK's next medicines challenge is operational delivery
The public standfirst identifies Varun Sharma as NEUVIOR's founder; subscriber access may be required.
Open publisher record - 06Founder commentary
Startups Magazine
What my dad's corner shop taught me
A first-person account published under the current name Varun Sharma.
Open publisher record - 07Founder commentary
BusinessCloud
Why neurodivergent founders can excel at building complex systems
A first-person account published under the current name Varun Sharma and explicitly connected to NEUVIOR and PHARMORIS.
Open publisher record
Identity record
One founder.
Two names across the record.
Varun Sharma
The current canonical public name for biographies, titles, metadata and new communications.
Varun Cruz
Used only when an original publisher, company, funding or intellectual-property record requires accurate attribution.
The historical records refer to the same person. The older name is preserved for transparent source reconciliation, not used as a competing identity or search device.
Campus status
Glasgow and Hyderabad remain proposals under test.
The visual ambition can be expansive. The current-status language must stay precise in both regions.
Glasgow / Scotland
A medicines and intelligent-systems campus direction.
The AMIDS and Glasgow Airport corridor is an area of interest for non-binding diligence, not a selected or controlled site.
- No secured land or site agreement
- No approved campus capital or construction programme
- No planning consent, operating licence or opening date
Hyderabad / Telangana
A distinct India pathway for future scientific capability.
The Hyderabad programme remains an early feasibility and partner-pathway concept with no selected or secured location.
- No selected site, land right or lease
- No approved capital, construction or commissioning route
- No licence, operating facility, partner commitment or opening date
Questions / answered directly
The useful answers, without the mythology.
01Who is the founder of VARUNÉ Labs?
Varun Sharma is the founder of VARUNÉ Labs and leads the development of its proposed Scottish campus concept.
02Why do some public records use Varun Cruz?
Varun Sharma is the current canonical public name. Some earlier company, funding, intellectual-property and editorial records use Varun Cruz for the same person. The historical name is retained only where accurate attribution requires it.
03Is VARUNÉ Labs Scotland already operating?
No. It is a predevelopment proposal. No site, planning consent, committed campus capital package, construction programme, operating licence or opening date has been secured or approved.
04How much non-dilutive funding has NEUVIOR secured?
NEUVIOR has secured £217,542.37 in non-dilutive project backing: £25,000 for VIONIX ZERO, £49,928 for PHARMORIS, up to £99,614.37 for the active Scottish Enterprise SMART:SCOTLAND project, and £43,000 in secured private non-dilutive match funding. Methodology: maximum signed grant values plus the £43,000 secured private match amount; not revenue, equity raised or a claim all cash is drawn. This is the founder/company track record, not committed capital for a VARUNÉ Labs campus.
05Where is the proposed campus planned?
The AMIDS and Glasgow Airport corridor is the preferred area for detailed, non-binding diligence. This is an area of interest, not a selected or controlled site.
06What is the development model?
The model begins with partner access and evidence. Internal facilities would be considered only when demand, quality, governance, economics and strategic value support the commitment.
07Does VARUNÉ Labs have partnerships with organisations named on this site?
No relationship should be inferred from a contextual reference. Any partnership would be described only after written agreement and permission to publish it.
08Does the publication record mean the outlets endorse VARUNÉ Labs?
No. The records include founder commentary, a reader letter and publisher-authored coverage of a proposal. Publication does not establish endorsement, partnership, investment, adoption or support for VARUNÉ Labs.
09What is the relationship with VYRONIS?
VYRONIS is presented here only as a separate founder-led research direction. This page does not claim a current VYRONIS legal entity, partner, funding, facility, active programme, scientific validation or legal relationship with VARUNÉ Labs.
10Is the Hyderabad campus operating?
No. The Hyderabad pathway remains a predevelopment concept. The site does not claim a selected or secured site, land right, committed campus capital, planning approval, construction, operating licences, commissioned laboratories, partner commitment or an opening date.
Source record
Identity, entity and relationship evidence.
Owned profiles, public registers and funding records have different evidential weight. Each source is labelled by what it can and cannot support.
- 01Varun Sharma: NEUVIOR founder profile
Owned-source record for the current public name, NEUVIOR role, PHARMORIS product role and historical-name reconciliation.
- 02NEUVIOR Pharmaceuticals Ltd officers: Companies House
Current public register record under the historical name Varun Cruz. A filed record does not validate every operating or biographical claim.
- 03Varun Cruz: UKRI Gateway to Research
Publicly records the founder's association with the PHARMORIS and VIONIX ZERO funded projects. The remaining secured NEUVIOR backing is identified separately in the funding ledger.
- 04NEUVIOR: UKRI Gateway to Research organisation record
Public record for the £49,928 PHARMORIS and £25,000 VIONIX ZERO Innovate UK awards. It is not a VARUNÉ campus-capital record.
- 05Scottish Enterprise SMART:SCOTLAND award: public coverage
Independent public coverage of Scottish Enterprise backing for NEUVIOR. The signed offer controls the exact maximum of £99,614.37 and the active project status.
- 06Founder thesis connecting NEUVIOR and VARUNÉ Labs
Owned analysis explaining that NEUVIOR is the current company, PHARMORIS the immediate product priority and VARUNÉ Labs a separate predevelopment concept.
- 07NEUVIOR Energy Ltd filing history: Companies House
Shows that the company formerly named VYRONIS Technologies Ltd was renamed. It does not establish a current VYRONIS legal entity or a legal relationship with VARUNÉ Labs.
Follow the work as it earns the next gate